This was obviously always the risk with a biotech, and all holders are aware of it. The upside was so tempting. But the kick in the guts is still that. In terms of cash burn, cutting back on this means a much longer story here (cutting staff, raising capital, renewing strategy etc). Can anyone recommend such as long book?
beginning of end ...., page-8
Add SNT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.3¢ |
Change
-0.001(2.94%) |
Mkt cap ! $42.58M | |||
| Open | High | Low | Value | Volume |
| 3.3¢ | 3.3¢ | 3.3¢ | $6.417K | 194.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 106747 | 3.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.3¢ | 228097 | 1 |
View Market Depth
| Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
| SNT (ASX) Chart |